Danske Bank A S Buys Shares of 869,122 Abbott Laboratories $ABT

Danske Bank A S bought a new position in shares of Abbott Laboratories (NYSE:ABT) during the 3rd quarter, Holdings Channel reports. The fund bought 869,122 shares of the healthcare product maker’s stock, valued at approximately $116,410,000.

Other large investors have also made changes to their positions in the company. Carr Financial Group Corp boosted its holdings in Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after buying an additional 76 shares in the last quarter. Gemmer Asset Management LLC increased its holdings in Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 78 shares in the last quarter. Global Financial Private Client LLC lifted its position in shares of Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after acquiring an additional 79 shares during the period. Citizens & Northern Corp lifted its position in shares of Abbott Laboratories by 0.4% during the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock valued at $2,930,000 after acquiring an additional 79 shares during the period. Finally, Nia Impact Advisors LLC grew its holdings in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ABT. Barclays dropped their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Daiwa Securities Group cut their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Leerink Partners dropped their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Insider Buying and Selling at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $110.80 on Wednesday. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.06. The company has a market capitalization of $192.98 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 1.75 and a beta of 0.74. The stock has a fifty day moving average of $113.91 and a two-hundred day moving average of $123.50. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.